Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of intermittent use of elismetrep for treating acute migraine attacks. This Phase 3 study compares two doses of elismetrep, 10 mg and 20 mg, to understand their safety profiles over an average of one year. The study involves adult participants who have previously used elismetrep in an acute treatment trial and met compliance requirements. Participants are randomly assigned to receive either 10 mg or 20 mg of elismetrep taken orally during migraine attacks. The study uses a triple-masked design to ensure unbiased results. The treatment period spans approximately one year, during which safety and adverse events are closely monitored. This includes tracking any adverse events leading to discontinuation or serious adverse events related to the study drug. During the study, participants will complete electronic diaries to record migraine episodes and medication use. They will also attend scheduled visits to assess safety and tolerability, including monitoring for adverse events. The research team will measure the proportion of participants experiencing treatment-emergent adverse events and serious adverse events through study completion. Participants are expected to use a personal smartphone to maintain study diaries and comply with study procedures throughout the study duration.
Actively Recruiting
Researchers are evaluating the effect of LY3457263 compared with placebo on hemoglobin A1c HbA1c levels in adults with type 2 diabetes who have not reached their HbA1c goals despite stable treatment with semaglutide or tirzepatide. This phase 2, double-blind study aims to better understand how LY3457263 impacts blood sugar control in this population. Participants will receive once-weekly subcutaneous injections of either LY3457263 at one of three doses or a placebo, while continuing their stable dose of semaglutide or tirzepatide. The treatment period lasts 24 weeks, during which participants blood sugar and body weight changes will be monitored. The study includes a randomized, parallel-group design comparing these interventions. During the approximately 9-month study, participants will undergo assessments including measurements of HbA1c, fasting serum glucose, and body weight at baseline and week 24. Researchers will monitor safety and treatment effects throughout the study. Participants will have scheduled visits for treatment administration and evaluation, with the primary focus on HbA1c change from baseline at 24 weeks.
Actively Recruiting
Researchers are studying chronic migraine, a condition causing moderate to severe headaches often on one side of the head, sometimes with nausea, vomiting, and sensitivity to light or sound. This trial evaluates how well the medicine atogepant works compared to a placebo in preventing chronic migraine in participants aged 12 to 17 years. The study also monitors adverse events to assess safety. Participants will be randomly assigned to receive either oral atogepant tablets or placebo once daily for 12 weeks. This double-blind study means neither the participants nor the doctors know who receives the medicine or placebo. Following the treatment, participants will be observed for an additional 4 weeks. During the study, participants will visit hospitals or clinics regularly for assessments. They will complete daily diaries, undergo medical evaluations, blood tests, side effect checks, and questionnaires. The main outcomes include tracking adverse events and changes in monthly migraine days, along with measures of headache days, medication use, and quality of life over approximately 16 weeks.
Actively Recruiting
The trial investigates how well AZD6234 works and its safety in adults who have Type 2 Diabetes Mellitus along with obesity or excess weight. This Phase III, global, randomized, double-blind study compares AZD6234 to a placebo to measure changes in body weight over 68 weeks of treatment. The study aims to better understand weight loss effects and related health changes in this population. Participants will be randomly assigned to one of three groups two different doses of AZD6234 or a placebo. The treatments are given by weekly subcutaneous injections. The study will last 68 weeks, during which participants receive their assigned injections and are monitored regularly for effectiveness and safety. Throughout the study, participants will attend multiple visits for evaluations, including body weight, waist circumference, blood pressure, and lab tests such as haemoglobin A1C and triglycerides. Some may undergo DXA scans to measure fat mass. Researchers will track changes from baseline to assess weight loss and metabolic effects. Safety and tolerability will also be monitored over the treatment period, which lasts about 68 weeks.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of elismetrep compared with a placebo for treating acute migraine attacks. This randomized, double-blind, phase III trial is conducted at multiple outpatient centers and sponsored by TriGemX Bio, Inc. The study focuses on adults aged 18 to 75 years who experience moderate to severe migraines lasting 4 to 72 hours, with a history of at least 2 but no more than 10 migraine attacks per month. Participants are randomly assigned to one of three groups elismetrep 10 mg, elismetrep 20 mg, or placebo. All treatments are taken orally during a migraine attack. The trial uses a parallel study design and is triple-blinded to ensure unbiased results. The main study period extends until February 2027, with participants monitored for responses two hours after dosing. During the study, participants will complete questionnaires and use an electronic diary on their smartphones to track migraine symptoms and treatment effects. Researchers will assess outcomes such as pain freedom, relief from bothersome symptoms, and functional disability at two hours post-dose. Additional evaluations include monitoring for adverse events up to eight days after dosing. Participants must follow the study schedule and complete all trial procedures to help assess elismetreps potential as an acute migraine treatment.
Actively Recruiting
Researchers are evaluating the effects of AZD6793 in adults with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase IIb study compares two different doses of AZD6793 to placebo tablets to assess their efficacy and safety. The study is randomized, double-blind, placebo-controlled, and involves about 970 participants worldwide. Participants will be randomly assigned to one of three groups two different doses of AZD6793 or a matching placebo. The study lasts for 24 weeks, during which participants will take oral tablets of their assigned treatment. The trial aims to measure how well AZD6793 works to reduce COPD exacerbations compared to placebo. Throughout the study, participants will have regular assessments including lung function tests, symptom questionnaires, and blood tests to measure drug levels. Researchers will monitor the rate of COPD exacerbations, lung function changes, and symptom scores over 24 weeks. Safety and tolerability of the treatments will also be closely observed during this period.
Actively Recruiting
Healthy Volunteer
Researchers are studying the safety and immune response of a fifth dose of the Lyme disease vaccine called VLA15 in healthy individuals aged 7 years and older who have already received four doses of this vaccine. This Phase 3 trial compares the effects of the vaccine against a placebo saline to better understand its protection against Lyme disease. The study is randomized, placebo-controlled, and double-blinded, aiming to assess tolerability and immune response. Participants receive one injection, either VLA15 or saline, into the muscle of the upper arm at their first visit. They are randomized in a 51 ratio to either vaccine or placebo. The timing of the fifth dose varies, occurring either one or two years after the fourth dose from a previous study. The trial includes about 1712 participants and uses an independent data monitoring committee to oversee safety. During approximately 12 months of participation, individuals will attend four clinic visits. These visits include health checks, blood draws to measure immune response, and receiving the study injection during the first visit. Researchers will monitor local and systemic reactions within seven days post-injection, adverse events up to one month, and longer-term safety for up to a year. The main outcomes focus on immune responses to different parts of the vaccine and recording any side effects or new medical conditions.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.
Actively Recruiting
Migraine is a common neurological disorder causing moderate to severe headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. This research aims to evaluate the safety and effectiveness of ubrogepant, a medication approved for adults, in treating acute migraine attacks in children and adolescents aged 6 to 17 years. The study includes two groups a pharmacokinetic PK cohort for younger children and a main randomized study involving both children and adolescents. Participants aged 6 to 11 in the PK cohort will receive two different doses of ubrogepant to determine the appropriate dose for the main study. In the main study, after dose selection, children aged 6 to 11 and adolescents aged 12 to 17 will be randomly assigned to receive either a low dose, high dose of ubrogepant, or placebo, with a 1 in 3 chance of placebo assignment. For qualifying migraine attacks, participants will take oral tablets of the assigned study intervention and may take a second dose or rescue medication at least 2 hours later if the headache persists. Participants will attend regular visits at a hospital or clinic for up to 6 months. Researchers will monitor the effects of treatment through medical assessments, blood tests, side effect checks, and questionnaires. The main outcome measured is the percentage of participants who are free from pain 2 hours after the initial dose. Safety and tolerability will also be assessed throughout the study duration.